LT2768524T - Pd-l1 grindžiama imunoterapija - Google Patents

Pd-l1 grindžiama imunoterapija

Info

Publication number
LT2768524T
LT2768524T LTEPPCT/DK2012/050386T LT12780408T LT2768524T LT 2768524 T LT2768524 T LT 2768524T LT 12780408 T LT12780408 T LT 12780408T LT 2768524 T LT2768524 T LT 2768524T
Authority
LT
Lithuania
Prior art keywords
based immunotherapy
immunotherapy
Prior art date
Application number
LTEPPCT/DK2012/050386T
Other languages
English (en)
Inventor
Mads Hald Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of LT2768524T publication Critical patent/LT2768524T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
LTEPPCT/DK2012/050386T 2011-10-17 2012-10-17 Pd-l1 grindžiama imunoterapija LT2768524T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201170574 2011-10-17
PCT/DK2012/050386 WO2013056716A1 (en) 2011-10-17 2012-10-17 Pd-l1 based immunotherapy

Publications (1)

Publication Number Publication Date
LT2768524T true LT2768524T (lt) 2022-07-25

Family

ID=47115103

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/DK2012/050386T LT2768524T (lt) 2011-10-17 2012-10-17 Pd-l1 grindžiama imunoterapija

Country Status (15)

Country Link
US (1) US9669078B2 (lt)
EP (2) EP4079319A1 (lt)
JP (1) JP6259763B2 (lt)
CN (2) CN113444165A (lt)
BR (1) BR112014009526B8 (lt)
CA (1) CA2850245C (lt)
DK (1) DK2768524T3 (lt)
ES (1) ES2918580T3 (lt)
HR (1) HRP20220924T1 (lt)
HU (1) HUE059406T2 (lt)
LT (1) LT2768524T (lt)
PL (1) PL2768524T3 (lt)
PT (1) PT2768524T (lt)
SI (1) SI2768524T1 (lt)
WO (1) WO2013056716A1 (lt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2768524T1 (sl) * 2011-10-17 2022-09-30 Io Biotech Aps Imunoterapija na osnovi PD-L1
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
WO2015153969A1 (en) 2014-04-04 2015-10-08 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for t cell receptors
EP3936145A1 (en) * 2014-07-31 2022-01-12 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
HRP20211540T2 (hr) 2014-09-17 2022-05-13 Io Biotech Aps Sastavi cjepiva koji sadrže triptofan 2,3-dioksigenazu ili njene fragmente
JP6918333B2 (ja) * 2014-09-17 2021-08-11 学校法人近畿大学 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤
MX2017004708A (es) 2014-10-10 2017-10-12 Idera Pharmaceuticals Inc Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
CA2965528A1 (en) * 2014-11-14 2016-05-19 Liquid Genomics, Inc. Use of circulating cell-free rna for diagnosis and/or monitoring cancer
JP6535133B2 (ja) * 2015-05-15 2019-06-26 リーバー ジェネティクス シーオー., エルティーディー.Reber Genetics Co., Ltd. 新規のバキュロウイルスベクター及び使用の方法
CN108368507B (zh) * 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
AU2016322506B2 (en) 2015-09-16 2023-02-09 Io Biotech Aps Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof
EP3423087B1 (en) * 2016-03-04 2023-11-15 IO Biotech APS Combination therapy against cancer
TWI794662B (zh) * 2016-03-14 2023-03-01 瑞士商赫孚孟拉羅股份公司 用於降低pd-l1表現之寡核苷酸
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス,インコーポレイティド NaPi2b標的化抗体-薬物コンジュゲート及びその使用方法
JP2019517544A (ja) 2016-06-10 2019-06-24 アイオー バイオテック エーピーエスIO Biotech ApS Calr及びjak2ワクチン組成物
JP7267014B2 (ja) * 2016-06-21 2023-05-01 アイオー バイオテック エーピーエス 癌ワクチンにおける使用のためのpdl1ペプチド
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018140890A1 (en) * 2017-01-29 2018-08-02 Zequn Tang Methods of immune modulation against foreign and/or auto antigens
CN108503691B (zh) * 2017-02-25 2021-07-23 复旦大学 一种人pd-l1蛋白高亲和性肽及其应用
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體-藥物結合物之組合療法
JP7247097B2 (ja) 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規pd-l1標的dnaワクチン
WO2019101954A1 (en) * 2017-11-24 2019-05-31 Io Biotech Aps Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019126691A1 (en) 2017-12-21 2019-06-27 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
FR3086534B1 (fr) * 2018-10-01 2020-11-06 Univ Bordeaux Methode pour traiter une infection par le virus de l'immunodeficience humaine
KR20210084546A (ko) 2018-10-29 2021-07-07 메르사나 테라퓨틱스, 인코포레이티드 펩티드 함유 링커를 갖는 시스테인 조작된 항체-약물 접합체
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
WO2020181402A1 (zh) * 2019-03-10 2020-09-17 胡西木 一种抗肿瘤多肽及其应用
CN113249447A (zh) * 2019-04-26 2021-08-13 嘉兴允英医学检验有限公司 一种pd-l1表达水平检测的方法和试剂盒
WO2021055583A1 (en) * 2019-09-17 2021-03-25 Ohio State Innovation Foundation Human anti-pd-l1 peptide vaccines and methods of their use
WO2021208106A1 (zh) * 2020-04-18 2021-10-21 北京泽勤生物医药有限公司 一种治疗自身免疫病的融合肽
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
CA3220007A1 (en) * 2021-05-17 2022-11-24 Wisconsin Alumni Research Foundation Synthetic protein for inducing immune tolerance
KR102421307B1 (ko) * 2021-11-19 2022-07-14 을지대학교 산학협력단 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114702569B (zh) * 2022-05-25 2023-01-10 深圳吉诺因生物科技有限公司 Pd-l1相关疫苗及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CA2389722A1 (en) * 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
AU2002338272B2 (en) * 2001-04-02 2007-10-11 Dana-Farber Cancer Institute, Inc. PD-1, a receptor for B7-4, and uses therefor
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
ES2654064T3 (es) * 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
EP1576014B1 (en) * 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
AU2007342338A1 (en) * 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
WO2009026472A1 (en) * 2007-08-21 2009-02-26 The General Hospital Corporation Methods for inducing tolerance
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
US20130017199A1 (en) * 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
IL300733A (en) * 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeting immune modulation
SI2768524T1 (sl) * 2011-10-17 2022-09-30 Io Biotech Aps Imunoterapija na osnovi PD-L1

Also Published As

Publication number Publication date
CA2850245C (en) 2020-04-28
CN103917243A (zh) 2014-07-09
HRP20220924T1 (hr) 2022-10-28
EP4079319A1 (en) 2022-10-26
BR112014009526B8 (pt) 2023-01-17
JP6259763B2 (ja) 2018-01-10
EP2768524A1 (en) 2014-08-27
ES2918580T3 (es) 2022-07-19
PT2768524T (pt) 2022-07-05
BR112014009526B1 (pt) 2021-07-13
PL2768524T3 (pl) 2022-09-19
US20140242101A1 (en) 2014-08-28
BR112014009526A2 (pt) 2017-05-09
JP2014534202A (ja) 2014-12-18
SI2768524T1 (sl) 2022-09-30
DK2768524T3 (da) 2022-07-04
CA2850245A1 (en) 2013-04-25
HUE059406T2 (hu) 2022-11-28
US9669078B2 (en) 2017-06-06
CN113444165A (zh) 2021-09-28
EP2768524B1 (en) 2022-05-04
WO2013056716A1 (en) 2013-04-25
CN103917243B (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
SI2768524T1 (sl) Imunoterapija na osnovi PD-L1
HK1197182A1 (en) Cancer immunotherapy
DK3424953T3 (en) Terapeutiske antistoffer
PL3434695T3 (pl) Ulepszona immunoterapia
GB201103955D0 (en) Antibodies
EP2715659A4 (en) ABOUT FEED
GB201112056D0 (en) Antibodies
EP2673635A4 (en) IMMUNOTHERAPY THROUGH APOE
AP2014007621A0 (en) 2-Thiopyrimidinones
GB201117538D0 (en) Methods
EP2695208A4 (en) MICRO-THERMOCOUPLE
GB201120860D0 (en) Cancer immunotherapy
EP2679138A4 (en) Borescope
GB201301300D0 (en) No details
GB201119167D0 (en) Novel bachteriophages
DK2770906T3 (en) Applanationstonometer
ZA201403228B (en) Heterocyclypyri(mi)dinylpyrazole
EP2698098A4 (en) campimeter
EP2694655A4 (en) pavec
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
GB201303586D0 (en) No details
GB201115167D0 (en) No details